“Our study found that cannabis use among cancer patients is common [and that] cannabis [is] often obtained without oncologist involvement.”
Topic: Health/Safety
Researchers concluded: “Within six weeks on the therapy, median pain scores decreased significantly. There were no severe adverse events reported.”
“Sublingual CBD was found to be well-tolerated and provided statistically significant improvements in several BPS parameters,” investigators determined.
“Participants reported more energy and vitality [and] also better mental and general health status.”
The study’s authors concluded: “[C]ontinuous cannabis use over 2-years was not associated with an increased psychosis transition rate, and did not worsen clinical symptoms, functioning levels, or overall neurocognition.”
“Symptom improvement was reported by eight of nine patients, including improvements in abdominal pain and swelling, nausea, appetite, and general well-being.”
Investigators concluded, “Given the expanding access to cannabis products in the United States and around the world, more research, particularly longitudinal and experimental studies, is needed.”
Investigators concluded, “The total participant sample reported significantly improved anxiety, depression, fatigue, and ability to take part in social roles and activities.”